2Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B [ J ]. Hepatology, 2000,31 : 207 - 210.
3Liaw YF, Sung J J, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351:1521 -1531.
4Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection[J]. Gastrenterology, 2002, 123:1831 - 1838.
2Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antivir Res,2002,55: 381-396.
3Schneller SW. Carbocylic nucleosides (carbonucleosides) as new therapeutic leads. Curr Top Med Chem,2002:1087-1092.
4Marion PL, Salazar FH, Winters MA, et al. Potent effecacy of entecavir(BMS-200475) in a duck model of hepatitis B virus infection. Antimicrob Agents Chemother, 2002,46:82-88.
5Yamanaka G. Metabolic studies on BMS-200475,a new conpound active against hepatits B virus. Antimicrob Agents Chemother, 1999,43:190-193.
6Levine S. Efficacies of entecavir ngainst lamivudine-resistant hepatitis B virus replication and recombinatant polymerases in vitro. Antimicrob Agents Chemother, 2002,46: 2525-2532.
7Bifano M. Hepatic impairment does not alter single-does pharmacokinetics and safety of entecavir. Hepatology, 2004,40: ( 4 suppl. 1 ): 1149.
8Wolters LM, Hansen BE, Niesters HE, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol,2002,37:137-144.
9Chang T. Sustained viral load and ALT reduction following 49 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.Hepatology, 2002,36.
10Schiff ER. Entecavir 1.0 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine refractory patients. Hepatology, 2004,40:(4 suppl. 1): 131.
5Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
7Gish R G,Lok A S,Chang T T,et al. Entecavir Therapy for up to 96 Weeks in Patients with HBeAg-positive Chronic Hepa-titis B[J]. Gastroenterology, 2007,133 (5) : 1437-1444.
8[2]Perrillo RP,Wrihgt T,Rakela J,et al.A multicenter United States-Canadian trail to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B[J].Hepatology,2001,33(2):424-432.
9[3]Hann HW,Fontana RJ,Wright T,et al.A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis[J].Liver Transpl,2003,9(1):49-56.
10[6]Forman LM,Lucey MR.Predicting the prognosis of chronic liver disease:an evolution from child to MELD.Mayo End-stage Liver Disease[J].Hepatology,2001,33(2):473-475.
